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Abstract
Enriching existing predictive models with new biomolecular mark-
ers is an important task in the new multi-omic era. Clinical studies
increasingly include new sets of omic measurements which may prove
their added value in terms of predictive performance. We introduce a
two-step approach for the assessment of the added predictive ability of
omic predictors, based on sequential double cross-validation and reg-
ularized regression models. We propose several performance indices
to summarize the two-stage prediction procedure and a permutation
test to formally assess the added predictive value of a second omic
set of predictors over a primary omic source. The performance of the
test is investigated through simulations. We illustrate the new method
through the systematic assessment and comparison of the performance
of transcriptomics and metabolomics sources in the prediction of body
mass index (BMI) using longitudinal data from the Dietary, Lifestyle,
and Genetic determinants of Obesity and Metabolic syndrome (DIL-
GOM) study, a population-based cohort from Finland.
Keywords: Added predictive ability; double cross-validation; regularized re-
gression; multiple omics sets
1 Introduction
During the past decade, much attention has been devoted to accommodate
single high-dimensional sources of molecular data (omics) in the calibration
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of prediction models for health traits. For example, microarray-based tran-
scriptome profiling and mass spectometry proteomics have been established
as promising omic predictors in oncology [1, 2, 3] and, to lesser extent, in
metabolic health [4, 5]. Nowadays, due to technical advances in the field and
evolving biological knowledge, novel omic measures, such as NMR proteomics
and metabolomics [6, 7] or nano-LCMS and UPLC glycomics [8, 9] are emerg-
ing as potentially powerful new biomolecular marker sets. As a result, it is
increasingly common for studies to collect a range of omic measurements in
the same set of individuals, using different measurement platforms and cover-
ing different aspects of human biology. This causes new statistical challenges,
among which the evaluation of the ability of novel biomolecular markers to
improve predictions based on previously established predictive omic sources,
often referred as their added or incremental predictive ability [10, 11, 12].
An illustrative example of these new methodological challenges is given
by our motivating problem. We have access to data from 248 individuals
sampled from the Helsinki area, Finland, within the Dietary, Lifestyle, and
Genetic determinants of Obesity and Metabolic syndrome (DILGOM) study
[6]. One-hundred-thirty-seven highly correlated NMR serum metabolites and
7380 beads from array-based transcriptional profiling from blood leukocytes
were measured at baseline in 2007, together with a large number of clinical
and demographic factors which were also measured in 2014, after seven years
of follow-up. Our primary goal is the prediction of future body mass index
(BMI), using biomolecular markers measured at baseline. More specifically,
we would like to compare the predictive ability of the available metabolomics
and transcriptomics, and to determine if both should be retained in order to
improve single-omic source predictions of BMI at seven years of follow-up.
In our setting, it is necessary to both calibrate the predictive model based
on each source of omic predictors and assess the incremental predictive ability
of a secondary one relative to the first set, using the same set of observations.
Hence, in order to avoid overoptimism and provide realistic estimates of
performance, it is necessary to control for the re-use of the data, which
has already been employed for model fitting within the same observations
[13, 14, 15]. This is a very important issue in omic research, where external
validation data are hard to obtain. It is well known that biased estimation of
model performance due to re-use of the data increases with large number of
predictors [16] and omic sets are typically high-dimensional (n < p, n sample
size and p the number of predictors). Extra difficulties in our setting are the
different dimensions (number of features), scales and correlation structure of
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each omic source, and possible correlation between omic sources induced by
partially common underlying biological information.
Evaluating the added predictive ability of new biomarkers regarding clas-
sical, low dimensional, settings has been a topic of intense debate in the bio-
statistical literature in the last years (see, for example, [11, 12, 18, 19] and
references therein). Getting meaningful summary measures and valid sta-
tistical procedures for testing the added predictive value are difficult tasks,
even when considering the addition of a single additional biomarker in the
classical regression context. In particular, widely used testing procedures for
improvement in discrimination based on area under the ROC curve (AUC)
differences [17] and net reclassification index (NRI) [10] have shown unac-
ceptable false positive rates in recent simulation studies [18, 19]. Overfitting
is a big problem when comparing estimated predictions coming from nested
regression models fitted in the same dataset. Moreover, the distributional
assumptions of the proposed tests seem inappropriate, translating into poor
performance of the aforementioned tests even when using independent vali-
dation sets [19].
To date, little attention has been given to the evaluation of the added
predictive ability in high-dimensional settings, where the aforementioned
problems are larger and new ones appear, such as the simultaneous inclu-
sion in an unique prediction model of predictors sets of very different nature.
Tibshirani and Efron [20] have shown that overfitting may dramatically in-
flate the estimated added predictive ability of omic sources with respect to
a low-dimensional set of clinical parameters. To solve this issue, they pro-
posed to first create a univariate ‘pre-validated’ omic predictor based on
cross-validation techniques [13, 14, 21, 22, 23] and incorporate it as a new
covariate to the regression with low-dimensional clinical parameters. In a
subsequent publication, Hoefling and Tibshirani [24] have shown that stan-
dard tests in regression models are biased for pre-validated predictors. As a
solution, the authors suggest a permutation test which seems to perform well
under independence of clinical and omic sets. Boulesteix and Hothorn [25]
have proposed an alternative method for the same setting of enriching clinical
models with a high-dimensional set of predictors. In contrast to [20, 24], they
first obtain a clinical prediction based on traditional regression techniques.
In a second step, the clinical predictor is incorporated as an offset term in
a boosting algorithm based on the omic source of predictors. Previous cal-
ibration of the clinical prediction is not addressed in the second step and
the same permutation strategy than Hoefling and Tibshirani [24] is used to
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derive p-values.
In this paper, we propose a two-step procedure for the assessment of addi-
tive predictive ability regarding two high-dimensional and correlated sources
of omic predictors. To the best of our knowledge, no previous work has ad-
dressed this problem before. Our approach combines double cross-validation
sequential prediction based on regularized regression models and a permuta-
tion test to formally assess the added predictive value of a second omic set
of predictors over a primary omic source.
2 Methods
Let the observed data be given by (y,X1,X2), where y = (y1, . . . , yn)
ᵀ is
the continuous outcome measured in n independent individuals and X1 and
X2 are two matrices of dimension n× p and n× q, respectively, representing
two omic predictor sources with p and q features. We assume that we are in
a high-dimensional setting (p, q > n) and that the main goal is to evaluate
the incremental or added value of X2 beyond X1 in order to predict y in
new observations. Our approach is based on comparing the performance of a
primary model based only on X1 with an extended model based on X2 and
adjusted by the primary fit based on X1.
2.1 Sequential estimation with two sources of predic-
tors
We propose a two-step procedure based on the replacement of the original
(high-dimensional) sources of predictors by their corresponding estimated
values of y based on a single-source-specific prediction model.
In the first step, we build a prediction model for y based on X1 and a
given model specification f . Based on the fitted model, the fitted values
p1 = fˆ(X1) = (p11, . . . , p1n)
ᵀ are estimated. Then, for each individual i, we
take the residual resi = yi− p1i. We consider res = (res1, . . . , resn)ᵀ as new
response and construct a second prediction model based on X2 as predictor
source:
p2 = E(res|X2) = f(X2) (1)
This is equivalent to including p1 as an offset term (fixed) in the model based
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on X2 for the prediction of the initial outcome y:
p2 = E(y|X2,p1) = f(X2) + p1 (2)
Several statistical methods are available to derive prediction models of
continuous outcomes in high-dimensional settings. In this work, we focus
on regularized linear regression models [16], where f(X) = Xβ and the
estimation of β is conducted by solving minβ(Xβ−Y)ᵀ(Xβ−Y)+λpen(β),
where pen(β) = 1−α
2
||β||22 + α||β||1. The penalty parameter λ regularizes
the β coefficients, by shrinking large coefficients in order to control the bias-
variance trade-off. The pre-fixed parameter α determines the type of imposed
penalization. We used two widely used penalization types: α = 0 (ridge, i.e.,
`2 type penalty [26]) and α = 1 (lasso, i.e., `1 penalty [27]). Note that
other model building strategies for prediction of continuous outcomes could
have been used in this framework, such as the elastic net penalization [28]
by setting α = 0.5, or boosting methods [39, 29, 40], among others.
2.2 Double cross-validation prediction
The use of a previously estimated quantity (p1) in the calibration of a pre-
diction model based on X2 (expressions (1) and (2)) requires, in absence of
external validation data, the use of resampling techniques to avoid bias in
the assessment of the role of p1 and p2. We use double cross-validation al-
gorithms [20, 22, 23, 24], consisting of two nested loops. In the inner loop
a cross-validated grid-selection is used to determine the optimal prediction
rule, i.e., for model selection, while the outer loop is used to estimate the
prediction performance by application of models developed in the inner loop
part of the data (training sets) to the remaining unused data (validation
sets). In this manner, double cross-validation is capable of avoiding the bias
in estimates of predictive ability which would result from use of a single-cross-
validatory approach only. In our setting, the outer loop of a ‘double’ cross-
validatory calculation allows obtaining ‘predictive’-deletion residuals which
fully account for the inherent uncertainty of model fitting on the primary
source (X1), before assessing the added predictive ability of X2, given by
p2. The basic structure of the double cross-validation procedure to estimate
unbiased versions of p1 and p2 is as follows:
Step 1 Obtain double cross-validation predictions of y, p1 = (p11, . . . , p1n),
based on X1:
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- Randomly split sample S in J mutually exclusive and exhaustive
sub-samples of approximately equal size S(1), . . . , S(J)
- For each j = 1, . . . , J , merge J − 1 subsamples into S(−j) = S − S(j)
- Randomly split sample S(−j) inK sub-samples (S(−j))(1), . . . , (S(−j))(K)
- For each k = 1, . . . , K, mergeK−1 subsubsamples into (S(−j))(−k) =
S(−j) − (S(−j))(k)
* Fit regression model y = f̂
(−k)
λl
(X1) +  for a grid of values
of shrinkage parameters λl, l = 1, . . . , L to (S
(−j))(−k)
* Evaluate f̂
(−k)
λl
,l = 1, . . . , L in the kth held-out sub-sample
(S(−j))(k) by calculating êkλl =
∑
(y,X1)∈(S(−j))(k)(y−f̂
(−k)
λl
(X1))
2
- Compute overall cross-validation error: ê
(−j)
λl
= 1
K
∑K
k=1 êλkl , l =
1, . . . , L
- Choose λ
(−j)
opt = minl=1,...,L(ê
(−j)
λl
) and calculate predictions of
y in the jth held-out sub-sample S(j), p
(j)
1 = f̂λ(−j)opt
(X1),
(y,X1) ∈ S(j)
- The vector of predictions of y, p1 = (p11, . . . , p1n) is obtained by con-
catenating the J p
(j)
1 , j = 1, . . . , J vectors, i.e., p1 = (p
(1)
1 , . . . ,p
(J)
1 )
Step 2 Repeat the process detailed in Step 1 considering the double cross-
validated residuals res = (y1 − p11, . . . , yn − p1n), as outcome and X2
as set of predictors and obtain the double cross-validation predictions
p2 = (p21, . . . , p2n)
ᵀ. Note that this is equivalent to obtaining the
double cross-validation predictions of y based on X2 considering p1 as
offset variable in the J fits of model (1).
2.3 Summary measures of predictive accuracy based
on double cross-validation
In order to evaluate the performance of the sequential procedure introduced
in Subsection 2.1., we propose three measures of predictive accuracy, de-
noted by Q2X1 , Q
2
X2|X1 , and Q
2
X1,X2
, based on sum of squares of the dou-
ble cross-validated predictions p1 and p2, obtained following the procedure
described in Subsection 2.2.. These summary measures can be regarded
as high-dimensional equivalents of calibration measurements for continuous
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outcomes in low-dimensional settings [30, 31], and an extension of previously
discussed proposals in the cross-validation literature [14].
Denote by PRESS(y,p) =
∑n
i=1(yi− pi)2 the prediction sum of squares
based on a vector of predictions p, obtained according to some arbitrary
model f , p = (p1, . . . , pn)
ᵀ = E(y|X) and by CV SS(p1,p2) =
∑n
i=1(p1i −
p2i)
2 the sum of squared differences between two cross-validated vectors of
predictions, e.g. p1 = Ef1(y|X1), p2 = Ef2(y|X2). Let p0 be the simplest
cross-validated predictor of y, based on the sample mean of y only. To
summarize the first step of the sequential procedure, we use double cross-
validation to estimate the predictive ability of X1 by
Q2X1 =
CV SS(p1,p0)
PRESS(y,p0)
=
∑J
j=1
∑
j∈S(j)
(
p1j − y(−j)
)2∑J
j=1
∑
j∈S(j) (yj − y¯(−j))2
. (3)
Intuitively, Q2X1 represents the proportion of the variation of the response
y that is expected to be explained by f(X1) in new individuals , re-scaled
by the total amount of prediction variation in the response y. In the worst
case scenario, when p1 = p0 (X1 as predictive as a null model based on the
mean of y) Q2X1 = 0 and Q
2
X1
= 1 if p1 = y. Since the computation of
p1j, j ∈ S(j) for each of the j = 1, . . . , J random splits of the sample S is
based on the observations not belonging to S(j), we proceed in an analogous
way to compute the average predicted variation of y. Hence, in order to get
an appropriate re-scaling factor, for each subset S(j), we compute y¯(−j), the
mean value of the outcome variable y calculated without the observations
belonging to S(j).
Assume that Q2X1 > 0, the contribution of the second omic source, X2,
in the prediction of y can be summarized by
Q2X2|X1 =
CV SS(p2,y − p1)
PRESS(y − p1,y − p1) =
∑J
j=1
∑
j∈S(j)
(
p2j − (yj − p1j)(−j)
)2
∑J
j=1
∑
j∈S(j)
(
yj − p1j − (yj − p1j)(−j)
)2 .
(4)
Q2X2|X1 accounts for the predictive capacity of f(X2), after removing the
part of variation in y that can be attributed to the first source of predictors
X1. Its computation relies on the squared difference between p2 (the double
cross-validated predictions resulting from the second step of the proposed
procedure in Subsection 2.2.) and the corresponding residual from the step
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1 (res = y − p1) based on X1, re-scaled by the remaining predicted varia-
tion on y after the first step of the procedure. As a result, Q2X2|X1 can be
regarded as the expected ability of X2 to predict the part of y, after adjust-
ing for the predictive capacity of f(X1) and accounting for all model fitting
in the first stage of the assessment. Following the same arguments used in
deriving expression (3), for each subset S(j), the computation of the aver-
age variation of res is based on (y − p1)(−j), i.e., excluding the observations
belonging to S(j). Note that in Step 1 of the sequential procedure J mod-
els are fitted, each based on S(−j), providing residuals with expected zero
mean (given specification (1)), i.e., (y − p1)(−j) ≈ 0, j = 1, . . . , J . Hence,∑J
j=1
∑
j∈S(j)
(
yj − p1j − (y − p1)(−j)
)2
≈∑ni=1 (yi − p1i)2 and thus
Q2X2|X1 ≈
∑n
i=1 p
2
2i∑n
i=1 (yi − p1i)2
. (5)
Finally, we derive a third summarizing measurement of the overall sequential
process, Q2X1,X2 , defined as:
Q2X1,X2 =
CV SS(p1 + p2,p0)
PRESS(y,p0)
=
∑J
j=1
∑
j∈S(j)
(
p1j + p2j − y¯(−j)
)2∑J
j=1
∑
j∈S(j) (yj − y¯(−j))2
. (6)
Q2X1,X2 represents the total predictive capacity of the overall sequential pro-
cedure based on X1 and X2, i.e., the combined predictive ability of X1 and
X2 given by p1 + p2. Note that Q
2
X1,X2
is based on the same squared differ-
ence between p2 and res = y−p1 as Q2X2|X1 , but the re-scaling factor refers
to the total predictive variation of the original response y.
The three introduced measures jointly summarize the performance of the
two omic sources under study and their interplay in order to predict the
outcome y. In all the cases higher values are indicative of higher predictive
ability. The three measurements vary between 0 (null predictive ability)
and the maximal value of 1. The interpretation of Q2X1 is straightforward,
as it simply captures the predictive capacity of the firstly evaluated omic
source. Note that the difference between Q2X2|X1 and Q
2
X1,X2
relies on the
denominator. In general, if X1 is informative, the denominator in expression
(4) will be smaller than in expression (6). Thus, the residual variation after
Step 1 will be smaller than the total initial variation.
The three summary measures are related by the following expression:
(1−Q2X1)(1−Q2X2|X1) ≈ (1−Q2X1,X2). (7)
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Consequently, we can rewrite Q2X2|X1 as follows:
Q2X2|X1 ≈
Q2X1,X2 −Q2X1
(1−Q2X1)
. (8)
Note that in cases in which Q2X2|X1 = 0, we get that Q
2
X1,X2
− Q2X1 = 0,
and viceversa. However, Q2X2|X1 and Q
2
X1,X2
− Q2X1 differ when not zero.
Specifically, from expression (8), we obtain that Q2X2|X1 ≥ Q2X1,X2 − Q2X1 .
In short, Q2X2|X1 may be regarded as the conditional contribution of X2 for
the prediction of y with respect to what may be predicted using X1 alone.
Q2X1,X2 − Q2X1 measures the absolute gain in predictive ability from adding
X2 to X1. Note that a given source X2 may present a large conditional
Q2X2|X1 but a small absolute Q
2
X1,X2
−Q2X1 (if, for example, X1 presents high
predictive ability itself). Moreover, due to the relation between p1 and the
resulting vector of predictions after combining X1 and X2, p1+p2, expression
(8) implies that Q2X1,X2 ≥ Q2X1 . This desirable property may not be fulfilled
using alternative combination strategies.
In practice, our sequential procedure relies on the realistic assumption of
positive predictive ability of the first source of predictors, X1 (one would only
be interested in assessing additional or incremental information on top of an
informative source itself). Accordingly, we advise to conduct our sequential
procedure using X1 as primary source only if Q
2
X1
> 0, which is, furthermore,
required to derive expression (8).
2.4 Permutation test for assessment of added predic-
tive ability
The summary measures may be used to introduce formal tests for assessing
the added or augmented predictive value of X2 over X1 to predict y. We
propose a permutation procedure to test the null hypothesis H0 : Q
2
X2|X1 = 0
against the alternative hypothesis H1 : Q
2
X2|X1 > 0. The test is based on per-
muting the residuals obtained after applying the first step of our two-stage
procedure with the data at hand. Our goal is to remove the potential asso-
ciation between X2 and y while preserving the original association between
y and X1.
Explicitly, we propose the following algorithm:
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Step 1 Calculate the residuals res = y− p1 based on the predictions p1 of
y based on X1, obtained in the first step of the procedure presented in
Section 2.1.
Step 2 Permute the values of res, obtaining respi and generate values of the
response y under the null hypothesis: y∗ = p1 + respi.
Step 3 Repeat the two-stage procedure from Section 2.1. for predicting y∗
and obtain the corresponding Q2∗X2|X1 .
The procedure is repeated M times and the resulting permutation p-
values are obtained as follows:
p-value =
1
M
M∑
i=1
I(Q2∗iX2|X1 > Q
2
X2|X1),
where M is the number of permutations, and Q2X2|X1 is the actual observed
value with the data at hand. Note that in Step 2, we generate a ‘null’ version
of the original response y and then we repeat the overall two-stage procedure,
which implies that the ‘null’ residuals used in Step 3 are not fixed and are,
in general, different from respi. This is necessary in order to capture all
the variability of the two-stage procedure and to correctly generate the null
hypothesis of interest. Moreover, the cross-validation nature of the procedure
protects against systematic bias of the residuals obtained in Step 3 based on
y∗ [see Chapter 7 of 16].
Given the aforementioned relations between Q2X1 , Q
2
X2|X1 , and Q
2
X1,X2
specified by expression (6) , note that H0 : Q
2
X2|X1 = 0 is equivalent to
H˜0 : Q
2
X1,X2
−Q2X1 = 0. This result immediately follows from expression (6),
given that Q2X2|X1 = 0 if and only if 1 − Q2X2|X1 = 1 (assuming Q2X1 6= 1).
Hence, both tests are equivalent provided that the distribution under the null
hypothesis is generated by the aforementioned permutation procedure, i.e.,
the p-values, resulting from using Q2X2|X1 as test statistic or Q
2
X1,X2
− Q2X1
are approximately the same.
Due to the reliance of our method on resampling techniques, computa-
tional cost is a potential limitation of our approach. However, our method
is easy to split in M independent realizations of the same computational
procedure. Hence, we can use parallel computing to speed up the procedure
[32].
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3 Simulation study
3.1 Simulation setup
We simulate two omic predictor sources X1 (dimension n × p) and X2 (di-
mension n×q) and a n×1 vector y, the continuous outcome. We use matrix
singular value decomposition (svd, [33]) of each of the two omic sources to
generate common ‘latent’ factors associated with X1, X2 and y. Common
eigenvectors in the svd of X1 and X2 introduce correlation among the omic
sources. We consider different patterns in terms of the conditional associa-
tion between X2 and y (see Figure 1). The details of the data generation
procedure are as follows:
X1
X2
LC
L1
L2
y X1
X2
LC
L1
L2
y
Figure 1: Simulation study. X1 and X2 are two omic predictors sources and
y is the outcome to be predicted. L1, L2 and LC are three independent non-
observed matrices used to generate X1 and X2. Correlation between X1 and
X2 is induced by LC . Left: Null case. No independent (of X1) association
between X2 and y (y generated as a linear combination of columns of LC
plus independent noise). Right: Alternative case. Independent (of X1) as-
sociation between X2 and y (y generated as a linear combination of L1 and
L2 plus independent noise).
Step 1 Generate L ∼ N(0, IR), a matrix of r = 1, . . . , R i.i.d. latent
factors of X1 and X2.
Step 2 Define Σ1 (p × p) and Σ2 (q × q), the correlation matrices of
X1 and X2, respectively, according to a predefined covariance structure of
interest. Following the recent literature on pathway and network analysis of
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omics data [34], we generated Σi, i = 1, 2 according to a hub observation
model [35, see Figure 2].
Step 3 Draw X∗i ∼ N(0,Σi), i = 1, 2, and obtain the singular value
decomposition for each of the independent matrices X∗1 and X
∗
2: X
∗
i =
U∗iDiVTi , i = 1, 2.
Step 4 Generate the final correlated X1 and X2 by manipulation of
U∗1 and U∗2, the left eigenvectors matrices from X∗1 and X∗2, respectively.
Specifically, for a certain number (C) of predefined columns C1 and C2,
the original submatrices U∗1C1 and U
∗
2C2 (independent) are replaced by C
common independent latent factors Lc, c = 1, . . . , C generated in Step 1.
In this manner, correlation between X1 and X2 is induced, while the within-
omic source correlation structures Σ1 and Σ2 are preserved.
Step 5 Simulate the outcome y = X1β1 + X2β2 + , where β1 and
β2 are vectors of regression coefficients of length p and q, respectively and
 ∼ N(0, 1). Since Xi = UiDiVTi , i = 1, 2, we can rewrite Xiβi = UiDiβ∗i
and thus βi = Viβ
∗
i , where β
∗
i represents the association between Xi and
the outcome y through the orthogonal directions given by Ui. Consequently,
we first generate β∗i and we then transform it to the predictor space by using
βi = Viβ
∗
i .
X2
20
40
60
80
20 40 60 80
−1.0
−0.5
0.0
0.5
1.0
Figure 2: Simulation study. Left: Correlation matrix of X1 (p = 1000), 4
groups of 250 features each. Right: Correlation matrix of X2 (q = 100), 2
groups of 50 features each.
Simulation 1 (‘Null’ scenarios): The second omic X2 source is non-
informative, i.e., β∗2 = 0, but is strongly correlated to X1, by imposing
common first columns of U1 and U2 (U11 = U21, the correlation between
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omic sources is driven through the maximal variance subspace). We con-
sidered different assumptions regarding the regression dependence of y on
X1 which has an impact on the ability to calibrate prediction rules based
on X1 for y. We consider two situations in which the association with y is
unifactorial, in the sense that only one latent factor (one column of U1) is
associated with y and two multi-factorial situations. One of our objectives is
to illustrate how changing the complexity of the calibration of a prediction
rule based on X1 (by formulating the problem through regression on either
larger or smaller variance latent factors) may affect the results. We consider
the following ‘null’ scenarios:
Scenario 1a β∗1m = 0.01, m = 1; β
∗
1m = 0, m 6= 1. y is associated to
high-variance subspace of U1, corresponding to the largest eigenvalue
of X1.
Scenario 1b β∗1m = 1, m = 6, β
∗
1m = 0, m 6= 6. The association with y
relies on a low-variance subspace of U1. Hence, we expect lower values
of Q2X1 , compared to Scenario 1a.
Scenario 1c β∗1m = 1, m = 1, 2, β
∗
1m = 0 otherwise. In this setting we
consider a bifactorial regression, as association with y is a combination
of the effect of the two first eigenvectors of X1.
Scenario 1d β∗1m = 1, m = 1, . . . , 4, β
∗
1m = 0 otherwise. In this setting
we consider a multifactorial regression, as association with y is a com-
bination of the effect of the four first eigenvectors of X1.
Simulation 2 (‘Alternative’ scenarios): X2 is associated with y through
latent factors non-shared with X1. The following ‘alternative’ scenarios are
investigated:
Scenario 2a β∗1m = β
∗
2m = 0.01, m = 1, β
∗
1m = β
∗
2m = 0, m 6= 1. The
eigenvector related to the largest eigenvalue of each source is associated
to y and the association between X1 and X2 is generated by sharing
the second eigenvectors, i.e., by setting U12 = U22.
Scenario 2b β∗1m = 0.01, m = 1, β
∗
1m = 0, m 6= 1 and β∗2m = 0.01, m = 3,
β∗2m = 0, m 6= 3, and the association between X1 and X2 is generated
by setting U11 = U21.
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Scenario 2c β∗1m = 0.01, m = 6, β
∗
1m = 0, m 6= 1 and β∗2m = 0.01, m = 3,
β∗2m = 0, m 6= 3, and the association between X1 and X2 is generated
by setting U11 = U21.
Figure 3 shows a Monte Carlo approximation based on a sample of n =
10, 000 observations of the regression coefficients β1 and β2 in the studied
simulated scenarios. From panels 3(a) to 3(d), we can observe that the differ-
ent simulation settings differ in the level of imposed sparsity in the association
between y and X1. On the one hand, scenarios presented in panels 3(a) (sce-
narios 1a, 2a ad 2b) and 3(b) (scenario 1b) are relatively sparse, with most
of the simulated coefficients close to zero. On the other hand, the β1 of sce-
nario 1c (represented in panel 3(c)) and specially of scenario 1d (represented
in panel 3(d)) are less sparse, based on a large number of non-null regression
coefficients in X1. With regard to β2, panel 3(e) (scenario 2a) represents a
sparser situation than panel 3(f) (scenarios 2b and 2b).
In our basic setting, we considered n = 100 observations, p = 1000 fea-
tures in X1 and q = 100 features in X2. For each scenario, we provide the
mean values and standard deviations of Q2X1 , Q
2
X2|X1 , and Q
2
X1,X2
, based on 5-
folds double cross-validation, jointly with the rejection proportions for testing
H0 : Q
2
X2|X1 along M = 500 Monte Carlo trials. We evaluated the permuta-
tion test introduced in Subsection 2.3. using nperm = 200 permutations. We
complemented our empirical evaluations of the proposed sequential double
cross-validation procedure by extending our basic simulation setting in two
directions. We checked the impact on modifying sample size (n = 50) and
the complexity of the problem by varying the number of variables considered
in the first stage (p = 4000).
Additionally, we compared the performance of our procedure based on
double-cross validation with two alternative strategies. On the one hand, we
provide results based on a two-stage procedure using a single cross-validation
loop (cross-validation is used for model choice but predictions and therefore
the residuals used as outcome in the second stage are directly computed on
the complete sample). On the other hand, we check the impact on the results
of over-penalization. Specifically, instead of taking λopt as defined in the inner
loop of the double cross-validation procedure presented in Subsection 2.1.,
we choose a larger value for λ, namely λopt + 1s.e.(λopt). Both are usual
strategies in penalized regression in single omic prediction frameworks, so it
is of practical interest to quantify their impact from the added predictive
value point of view. The results of these alternative strategies are provided
14
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Figure 3: Simulation study. (a)-(d): regression coefficients (elements of
β1, y-axis) corresponding to each of the p predictors of X1 (x-axis). (c)-
(d): regression coefficients (elements of β2, y-axis) corresponding to each
of the q predictors of X2 (x-axis). The outcome variable is generated as
y = X1β1 + X2β2 + ,  ∼ N(0, 1).(e)-(f) provide information about asso-
ciation between y and X1 and (e) and (f) corresponds to the independent
association between y and X2 in the alternative scenarios (for the null sce-
narios 1a-1d the independent association between y and X2 is null). (a)
corresponds to scenarios 1a, 2a and 2b, (b) correspond to scenarios 1b and
2c respectively, while (c) and (d) correspond to scenario 1c and 1d. (e) shows
the association (β2) between X2 and y in scenario 2a and (e) shows β2 for
scenarios 2b and 2c.
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as Supplemental material but discussed in the main text.
3.2 Simulation results
The results for the sequential double cross-validation procedure (labeled as
‘CV type= CVD, λopt’) are summarized in Tables 1 and 2. The top part of
each table contains the results concerning the ‘null’ scenarios (no added value
of X2), while the bottom part shows the results of the ‘alternative’ scenarios
(added value of X2). Table 1 contains results based on ridge regression, α = 0
in expression (1), while Table 2 summarizes the results for the lasso penalty
type (α = 1).
3.2.1 Ridge regression
For the four ‘null’ scenarios 1a-1d, given that X2 is not independently as-
sociated to y, we expect Q2X2|X1 = 0 and rejection proportions of H0 about
0.05.
The results of the sequential double cross-validation procedure based on
ridge regression are satisfactory in this regard, with rejection proportions
close to the nominal level in all the studied null scenarios and for different
sample sizes (n = 50, n = 100) and levels of complexity of the first step
(p = 1000, p = 4000).
The top part of Table 1 shows that the estimated Q2X1 for scenarios 1a,
1c and 1d are large and very similar (Q2X1 ∼ 0.90). As it was expected,
the estimated predictive ability of X1 is lower in scenario 1b and presents a
larger variability, since the association between y and X1 relies on a small
variance subspace. In general, for all 1a-1d scenarios the estimated Q2X2|X1
is close to zero. However, we observe that the sample size influences the
estimated Q2X1 and hence, due to the correlation between X1 and X2, also
affects the estimation of Q2X2|X1 . We observe systematically lower values of
QX1 for n = 50 than for n = 100 in all the studied ‘null’ scenarios. This
feature translates in systematically larger values of Q2X2|X1 for n = 50 than
for n = 100. However, the permutation test is able to account for this
issue and the level of the test is respected independently of the sample size.
Analogously, increasing the number of features of the first source X1 (from
p = 1000 to p = 4000) while keeping fixed the number of features of X2
(q = 100) also affects the estimation of QX1 and Q
2
X2|X1 . In this case, the
values of QX1 are larger and hence, the values of Q
2
X2|X1 tend to be closer to
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zero. Worth noting is that the level of the test is also well respected in this
case.
The bottom part of Table 1 shows the results for the alternative scenarios.
As desirable, the power increases with sample size for all the three studied
alternative scenarios. As it was the case for the ‘null’ scenarios, increasing
the sample size tends to lead to better predictive ability of X1. This result
matches intuition, since larger sample sizes provide more information for
model building, and hence, under correct model specification, the resulting
predicting models are expected to behave better in new data. An exception
to this is scenario 2c, where our double cross-validation procedure seems
to overfit with n = 50. This is due to the fact that scenario 2c, unlike
scenarios 2a and 2b, is characterized as a ‘difficult’ prediction problem when
considering X1 (association with y is driven by a low-variance subspace of
X1). In line with this, the power of the test is different for the three different
studied scenarios. The greatest power is reached in scenario 2a, in which the
independent association between X2 and y is driven through the subspace of
maximum variation and the first step of the procedure relies on a relatively
‘easy’ prediction problem.
Even if scenarios 2b and 2c are based on the same independent association
between X2 and y, the impact of the first source on the power of the test is
large. Scenario 2b, in which Q2X1 = 0.87 for n = 100 reaches a power of 71
%, while the rejection rate reduces to 19% in scenario 2c, corresponding to
a more ‘difficult’ prediction problem in the first stage, reflected in a low and
unstable Q2X1 (Q
2
X1
= 0.28 for n = 50 and Q2X1 = 0.09 for n = 100).
3.2.2 Lasso regression
Table 2 shows the results for double cross-validation procedure based on the
lasso specification (α = 1). With regard to the ‘null’ scenarios, we observe a
good performance for scenarios 1a and 1b, with rejection proportions close to
the nominal level. Interestingly, the rejection proportion of the permutation
test increases with sample size and the number of features in the first source
in scenarios 1c and 1d, which indicates a bad performance of the procedure
based on laso regression in these settings. Namely, the bad performance of
the lasso specification for scenario 1d does not improve by increasing sample
size (7% of rejections with n = 50, 9% of rejections with n = 100 and
36% of rejections for p = 4000). The reason behind this difference with
the ridge-based results is the mis-specification of the lasso with respect to
17
Table 1: Ridge (α = 0). Mean estimates (and standard deviation in brackets)
of Q2X1 , Q
2
X2|X1 , Q
2
X1,X2
and rejection proportions of the permutation test
based on Q2X2|X1 along 500 Monte Carlo trials.
Scenario n Q2X1 (Step 1) Q
2
X2|X1 (Step 2) Q
2
X1,X2
(Global) Rej. Prop.
n = 50 0.85 (0.03) 0.07 (0.09) 0.89 (0.05) 0.058
1a n = 100 0.88 (0.02) 0.03 (0.04) 0.91 (0.03) 0.068
n = 100, p = 4000 0.94 (0.02) 0.03 (0.04) 0.99 (0.01) 0.056
n = 50 0.31 (0.07) 0.04 (0.07) 0.34 (0.09) 0.044
1b n = 100 0.41 (0.07) 0.01 (0.02) 0.42 (0.07) 0.047
n = 100, p = 4000 0.50 (0.09) 0.01 (0.03) 0.72 (0.13) 0.060
n = 50 0.86 (0.03) 0.06 (0.08) 0.86 (0.04) 0.060
1c n = 100 0.91 (0.02) 0.02 (0.03) 0.92 (0.02) 0.050
n = 100, p = 4000 0.92 (0.05) 0.02 (0.04) 0.97 (0.05) 0.064
n = 50 0.83 (0.03) 0.05 (0.08) 0.84 (0.04) 0.046
1d n = 100 0.86 (0.02) 0.00 (0.00) 0.97 (0.01) 0.062
n = 100, p = 4000 0.88 (0.05) 0.00 (0.00) 0.97 (0.05) 0.044
n = 50 0.64 (0.13) 0.50 (0.15) 0.76 (0.16) 0.936
2a n = 100 0.68 (0.10) 0.60 (0.12) 0.91 (0.11) 0.997
n = 100, p = 4000 0.89 (0.05) 0.59 (0.08) 0.93 (0.06) 0.996
n = 50 0.84 (0.04) 0.16 (0.11) 0.93 (0.04) 0.236
2b n = 100 0.87 (0.03) 0.11 (0.06) 0.95 (0.01) 0.712
n = 100, p = 4000 0.88 (0.02) 0.10 (0.06) 0.94 (0.03) 0.652
n = 50 0.28 (0.07) 0.11 (0.11) 0.36 (0.11) 0.184
2c n = 100 0.09 (0.08) 0.01 (0.00) 0.13 (0.16) 0.186
n = 100, p = 4000 0.16 (0.09) 0.08 (0.06) 0.52 (0.09) 0.526
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the underlying data-generating mechanism. Lasso regression assumes that
the true model is sparse, while, as mentioned, scenario 1c and specially 1d
correspond to non-sparse solutions.
These findings illustrate how model mis-specification may result in an
improvement of predictions by adding a second source of predictors, not
because of independent association to the outcome, but just because of the
correlation with the first source of predictors.
The bottom part of Table 1 shows the results for the alternative scenar-
ios. With respect to the alternative scenarios (bottom part of Table 2), the
conclusions are similar to those observed for ridge regression. The power
increases with the sample size, and the rejection proportions differ across the
three scenarios. However, we observe that ridge outperforms lasso in terms
of power, specially for scenarios 2a and 2b.
3.2.3 Alternative procedures
Tables S3 and S4 summarize the results for the two aforementioned alterna-
tive strategies in the basic setting (p = 1000, q = 100) and two sample sizes
(n = 50, n = 100): ‘CVD, λ1se’ corresponds to the strategy in which the
sequential double cross-validation is over-shrunk (by taking λopt + 1s.e.(λopt)
instead of λopt in the inner cross-validation loop) and ‘CVS, λopt’ represents
the sequential procedure based on one single cross-validation loop (standard
residuals as opposed to deletion-based residuals).
In general, these two alternative strategies provide different estimates
for the predictive ability of the two studied sources of predictors. Taking
the double-cross validation approach as gold-standard, we observe that the
over-shrinkage of the predictions in the first step of the ‘CVD, λ1se’ method
provokes an under-estimation of Q2X1 , while the ‘CVS, λopt’ provides an over-
estimation, specially when the association between outcome and first source
of predictors is driven through a low-variance space. For example, in the
scenario 1b, for n = 100, Q2X1 = 0.69 when based on a single cross-validation
approach, notably larger than Q2X1 = 0.41 estimated by the double cross-
validation approach. Moreover, we observe that the effect of re-using the data
is larger for small sample sizes, with systematically larger Q2X1 for n = 50
than for n = 100. However, under the null hypothesis, the introduced bias
on the first step for both alternatives does not translate in an inflated type I
error. The method labeled as ‘CVD, λ1se’, based on double cross-validation
but based on under-fitting by over-penalization controls the false discovery
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Table 2: Lasso (α = 1). Mean estimates (and standard deviation in brackets)
of Q2X1 , Q
2
X2|X1 , Q
2
X1,X2
and rejection proportions of the permutation test
based on Q2X2|X1 along 500 Monte Carlo trials.
Scenario n Q2X1 (Step 1) Q
2
X2|X1 (Step 2) Q
2
X1,X2
(Global) Rej. Prop.
n = 50 0.79 (0.06) 0.15 (0.14) 0.88 (0.05) 0.058
1a n = 100 0.86 (0.03) 0.05 (0.06) 0.91 (0.03) 0.054
n = 100, p = 4000 0.89 (0.02) 0.10 (0.06) 0.95 (0.01) 0.140
n = 50 0.18 (0.11) 0.08 (0.12) 0.27 (0.16) 0.056
1b n = 100 0.33 (0.09) 0.02 (0.04) 0.35 (0.09) 0.056
n = 100, p = 4000 0.44(0.07) 0.03 (0.05) 0.45 (0.07) 0.058
n = 50 0.80 (0.05) 0.12 (0.13) 0.84 (0.05) 0.054
1c n = 100 0.89 (0.02) 0.04 (0.05) 0.90 (0.03) 0.068
n = 100, p = 4000 0.85 (0.28) 0.13 (0.09) 0.90 (0.03) 0.352
n = 50 0.67 (0.06) 0.14 (0.12) 0.72 (0.07) 0.070
1d n = 100 0.83 (0.03) 0.05 (0.05) 0.85 (0.03) 0.094
n = 100, p = 4000 0.73 (0.04) 0.12 (0.09) 0.78 (0.04) 0.360
n = 50 0.58 (0.09) 0.44 (0.14) 0.69 (0.13) 0.768
2a n = 100 0.67 (0.07) 0.53 (0.09) 0.90 (0.03) 1.000
n = 100, p = 4000 0.84 (0.04) 0.47 (0.09) 0.84 (0.06) 1.000
n = 50 0.77 (0.07) 0.21 (0.15) 0.89 (0.06) 0.106
2b n = 100 0.84 (0.04) 0.12 (0.09) 0.92 (0.02) 0.481
n = 100, p = 4000 0.83 (0.02) 0.18 (0.09) 0.96 (0.02) 0.506
n = 50 0.15 (0.10) 0.12 (0.13) 0.28 (0.17) 0.086
2c n = 100 0.27 (0.09) 0.09 (0.07) 0.33 (0.11) 0.351
n = 100, p = 4000 0.07 (0.07) 0.06 (0.06) 0.43 (0.07) 0.227
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rate under the null hypothesis in similar fashion than the procedure introduce
in Subsection 2.1. With regard to the method based on single cross-validation
(‘CVS, λopt’), its behavior is slightly conservative under the null hypothesis.
For the alternative scenarios, as Q2X1 , Q
2
X2|X1 and Q
2
X1,X2
, are underes-
timated by ‘CVD, λ1se’, while ‘CVS, λopt’ overfits both. Even if power in-
creases with sample size, both methods are systematically less powerful than
our proposal,‘CVD, λopt, which makes it the preferable method from both an
estimation and testing point of view.
4 Application: DILGOM data
To illustrate the performance of the proposed sequential double cross-validation
procedure, and to compare it to the alternative strategies discussed in Section
3, we analyzed data from the DILGOM study. We are interested in the abil-
ity of serum NMR metabolites and microarray gene expression levels in blood
to predict body mass index (BMI) at 7 years of follow-up. The metabolomic
predictor data consists of quantitative information on 137 metabolic mea-
sures, mainly composed of measures on different lipid subclasses, but also
amino acids, and creatine. The gene expression profiles were derived from Il-
lumina 610-Quad SNParrays (Illumina Inc., San Diego, CA, USA). Initially,
35,419 expression probes were available after quality filtering. In addition
to the pre-processing steps described by [6], we conducted a prior filtering
approach and removed from our analyses probes with extremely low varia-
tion (see [36] for details on the conducted pre-processing). As a result, we
retained measures from 7380 beads for our analyses. The analyzed sample
contained n = 248 individuals for which both types of omic measurements
and the BMI after 7 years of follow-up (mean=26 kg/m2, sd=5 kg/m2) were
available. We carried out two distinct analyses using the added predictive
value assessment approach described in this paper. As a first analysis, we
consider the metabolic profile as primary omic source for the prediction of
the log-transformed BMI and we evaluated the added predictive value of
blood transcriptomics profiles. This approach is the most relevant in prac-
tice, because of both biological and economical reasons. On the one hand,
metabolome (which contains, among other, cholesterol measures) is presum-
ably more predictive of BMI than gene expression in blood. On the other
hand, NMR technology is typically more affordable [37] than available tech-
nologies for transcriptomic profiling, so favoring the NMR source seems a
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sensible approach in our setting. Nevertheless, to illustrate the properties of
our method, we also consider a second analysis in which we reversed the roles
of the omic sources, first fitting a model based on gene expression and then
evaluating the added predictive value of the metabolome. As in the simu-
lation study, we considered ridge and lasso regression as prediction models,
using the same alternative strategies to the sequential double cross-validation
procedure presented in section 3 (‘CVD, λopt’): ‘CVD, λ1se’, and ‘CVS, λopt’.
The main findings are summarized in Table 3. To check stability of the re-
sults, we artificially reduced the sample size of the available DILGOM data
and checked the impact on the estimation of the added predictive ability
with our sequential double cross-validation approach and its corresponding
p-value. We also compared our method with a naive approach, consisting
in stacking both metabolites and transcriptomics, and hence ignoring their
different origin. The results of these two additional analyses are given as
Supplemental Materials.
The upper part of Table 3 shows the results from our primary analysis,
focused on evaluating the added predictive ability of gene expression with
respect to our primary omic set, NMR-metabolomics, in the context of pre-
diction of future BMI. We observe that NMR-metabolomics itself presents a
moderately large predictive ability. Both ridge and lasso regression provide
very similar Q2Metab values which are slightly larger than 30% (Q
2
Metab = 0.305
for ridge regression, Q2Metab = 0.343 for lasso regression). According to
the results shown in the third and forth columns of Table 3, we observe
a highly significant positive added predictive ability of gene expression with
regard to log-transformed BMI after 7 years of follow-up. The size of such
added predictive ability (summarized by Q2GE|Metab) indicates a modest incre-
mental contribution of gene expression, very similar for the two considered
regularization methods (Q2GE|Metab = 0.071 according to ridge regression,
Q2GE|Metab = 0.090 for lasso regression). The final estimated combined pre-
dictive ability of metabolites and transcriptomics is slightly larger than 40
% (Q2Metab,GE = 0.415 according to ridge regression, Q
2
Metab,GE = 0.458 for
lasso regression). In summary, our main analysis suggests that adding gene
expression to an existing model based on NMR-metabolome will potentially
lead to a significant improvement in the prediction of BMI at 7 years of
follow-up.
The lower part of Table 3 contains the results of our secondary analysis,
in which we consider gene expression as primary source and we evaluate the
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Table 3: Application to DILGOM data. Alternative cross-validation strate-
gies. P-values based on 1000 permutations
α CV type Q2Metab Q
2
GE|Metab Q
2
Metab,GE p-value
α = 0 CVD,λopt 0.305 0.071 0.415 < 0.001
α = 0 CVD,λ1se 0.090 0.006 0.102 < 0.001
α = 0 CVS,λopt 0.291 0.137 0.447 0.001
α = 1 CVD,λopt 0.343 0.090 0.458 0.004
α = 1 CVD,λ1se 0.073 0.004 0.083 0.018
α = 1 CVS,λopt 0.374 0.060 0.457 0.035
α CV type Q2GE Q
2
Metab|GE Q
2
GE,Metab p-value
α = 0 CVD,λopt 0.092 0.194 0.327 < 0.001
α = 0 CVD,λ1se 0.019 0.091 0.117 < 0.001
α = 0 CVS,λopt 0.153 0.191 0.380 0.003
α = 1 CVD,λopt 0.277 0.102 0.453 < 0.001
α = 1 CVD,λ1se 0.043 0.122 0.204 < 0.001
α = 1 CVS,λopt 0.372 0.012 0.409 0.490
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addition of metabolomics. As expected, we observe a better performance of
NMR-metabolome than transcriptomics to predict future BMI, for both ridge
and lasso regression. In contrast to metabolites, for which the estimated value
of Q2Metab was only marginally affected by the two considered regularization
methods, the type of shrinkage plays a more important role when considering
gene expression (Q2GE = 0.092 with ridge regression, Q
2
GE = 0.277 with lasso
regression). Accordingly, the estimated added predictive value of metabolites
with respect to a primary model based on gene expression is strongly affected
by shrinkage type. Namely, metabolome explains around 19% of the remain-
ing variation of the outcome after accounting for the ridge-regression-based
prediction calibration using gene expression data, while the equivalent added
predictive ability of metabolome drops to 10% if we model gene expression
with a lasso penalty in the first step. Interestingly, when considering lasso
regression, the impact of the considering transcriptomics or metabolomics
as primary source is small, and in fact, the resulting predictive ability after
the overall process is similar for both sequential models (Q2Metab,GE = 0.458,
Q2GE,Metab = 0.453).
The results are supported by our first supplementary analysis consisting
of artificially reducing the sample size of the available DILGOM data to check
the stability of the estimated added predictive ability of the considered omic
sources, measured through Q2Metab|GE and Q
2
GE|Metab. In Table S1 we observe
that the results based on a random subsample of the data of n = 100 indi-
viduals are similar to those obtained with the actual sample, which indicates
that the estimated added predictive values shown in Table 3 are reflecting the
independent contribution of the secondary source in the prediction of BMI
and not the effect of recalibrating the primary source through the second
one due to scarcity of data in the first stage. That seems to be the case if
we consider a random subsample of the DILGOM data of n = 50, when the
added predictive ability of the secondary source is presumably overestimated
due to the underestimation of the predictive ability of the primary source in
the first stage of the procedure.
Our second supplementary analysis also supports our sequential approach.
Table S2 shows the estimated values of Q2Metab,GE for two models in which
simultaneously model both sources of predictors (without and with scaling).
These results show that stacking both omic sources is a bad strategy, even
with previous scaling of the two sources of predictors to avoid the impact of
the different scale of metabolomics and transcriptomics. For both ridge and
lasso specifications, we observe that the joint models based on stacking tran-
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scriptomics and metabolomics provide lower Q2Metab,GE = Q
2
GE,Metab values
than the initial Q2Metab.
With regard to the alternative strategies, Table 3 shows that the use of
a single cross-validation approach overestimates the role of gene expression
when considered alone (‘CVS, λopt’ approach provides a considerably larger
Q2GE than ‘CVD, λopt’), while the impact on Q
2
Metab is lower (due to its fewer
number of features, 139 metabolites versus more than 7000 gene expression
features). Accordingly, we also observe that the impact of overfitting the
residuals is larger when the first source is gene expression. Especially for lasso
regression (for which we observe the absolute largest difference between ‘CVS,
λopt’ and ‘CVD, λopt’ in the first step), we see how the added predictive value
of metabolome is obscured by the overfitting of the first source (Q2Metab|GE =
0.012 clearly not significantly different from 0).
With respect to the over-shrinkage of the penalty parameter in the inner
loop of the double cross-validation (‘2CV, λ1se’), it leads to a more pessimistic
estimation of the summary measures in each of the steps of the procedure,
particularly when using ridge regression and the case where the gene expres-
sion is the second source to be considered (Q2GE|Metab = 0.014).
5 Summary and discussion
In this paper, we addressed the problem of evaluating the added predictive
ability of a high-dimensional omic dataset for prediction of continuous out-
comes in the context of multiple and possibly correlated omic datasets.
We proposed a sequential method which consists of considering the vec-
tor of residuals based on the primary source of predictors as outcome when
fitting a prediction model based on the secondary source of omic predictors.
This is equivalent to introducing the vector of individual predictions based on
the primary source as an extra covariate with fixed weight when fitting a pre-
diction model for the original outcome based on the secondary source of omic
predictors. The use of a vector of predictions (which are fitted themselves)
in a subsequent prediction model requires cross-validation to account for the
uncertainty of calibrating the first source of predictors in the procedure. We
have proposed several summary measures, all of them based on double cross-
validation predictions. Moreover, we have introduced a permutation test to
formally test for added predictive ability of the secondary source.
In our approach, the first source of predictors is prioritized. Several rea-
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sons may motivate such an asymmetric approach to combination. On the
one hand, available omic sources typically differ in cost and interpretability,
and hence researchers may be interested in prioritizing more economic and
interpretable sources. This was the case in our real data application based on
the DILGOM study. NMR metabolomics measurements are more affordable
than transcriptomic profiling, and also more interpretable in the context of
BMI prediction. Hence, favoring NMR measurements seems logical in our set-
ting. Similar reasons are typically used to favor classical clinical parameters
when evaluating the addition of omic sources to clinical models. One could,
for instance, add a novel (biomolecular) marker set, e.g., metabolome, to a
set of clinical features such as glucose, blood pressure, and serum cholestrol,
which may potentially be correlated to the metabolome markers [20, 24, 25].
On the other hand, our sequential approach entails a functional relation be-
tween the first (single-source) prediction rule and the second (based on both
available omic sources) prediction model, which facilitates interpretation and
avoids both mathematical and philosophical problems arising from combined
models which may perform worse than the primary single-omic model. As
we have shown in our real data application, the approach, widely used in
low-dimensional settings, consisting of stacking X1 and X2 and calibrating a
new model f(X1,X2), is problematic in the multi-omic setting. Such strat-
egy does not guarantee that Q2X1,X2 ≥ QX1 , i.e., the combined model often
performs worse than one of the single-source models.
We have focused on the case in which external validation datasets are
not available and, hence, researchers have to fit and compare the predictive
performance of different models using the same set of patients (internal val-
idation). This is a common situation in practice. Epidemiological studies,
such as the Finrisk (DILGOM), expand their clinical databases by including
sequences of novel (omic) biomarker measure sets, which cover different bio-
logical processes and which are obtained using different technologies. Access
to equivalent data from other studies is typically hard to obtain. Moreover,
due to technical and economical reasons, these new sets of markers are typ-
ically evaluated on a reduced number of individuals of the study, leading to
n < p situations.
Closely connected to the difference between the internal and external val-
idation, is the issue of choice between standard classic (lack-of-fit) residuals
and the deletion-prediction residuals employed in this paper. Use of standard
residuals may suffice when adding novel predictor data to an established and
known (external) risk score, but in general greater caution should be applied.
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Nevertheless, use of standard residuals from previous model fitting when as-
sessing added-value still seems to be the norm in most analyses. This applies
not only to biostatistics [25], but also to related fields such as chemometrics
[38]. We have shown through simulations and the analysis of the DILGOM
data that use of deletion-residuals is essential to avoid substantial bias in the
assessment of the added value of a secondary predictor set, when added to
a primary set using the same patient data. Failure to do so renders results
essentially meaningless and non-interpretable.
Another feature of our method is that it does not only account for the
predictive capacity of the first predictor set, but it is also dependent on
model choice. Hence, our added prediction assessment is not just evaluating
the predictive impact of a secondary set of measurements in its own right,
but rather the joint impact of choice of predictors, model and estimation
approach.
Our application to real data shows that better predictions can be obtained
by adding transcriptomics to a model based on NMR-metabolomics, outper-
forming single-omic predictions. We have also illustrated the impact of model
misspecification in our approach and shown that naive approaches which ig-
nore the different nature, size and scale of the considered source of predictors
fail, providing worse results than model based on NMR-metabolomics only.
The present work may be extended in several directions. The two-step
sequential approach presented for continuous outcome may also be imme-
diately extended to other outcome types, particularly to the classification
context (binary outcome) and to time-to-event data, for which generaliza-
tions of linear regularized regression in high-dimensional settings are avail-
able. Summary performance measures as Q2X1 and Q
2
X1,X2
can be still derived
in the binary outcome context. However, given its reliance on the residuals,
the extension of the conditional Q2X2|X1 to the binary and survival contexts
is not straightforward. Also, the proposed testing procedure needs major
modification when considering more complex responses. Moreover, in the
implementation of the augmented assessment method, alternative prediction
rules could also be used, beyond linear regularized regression considered here.
Boosting algorithms might be an interesting choice worthy of further study
in the high-dimensional augmented predictive framework, as an extension of
[25], including more complex model specifications, such as non-linear and
interaction terms [39, 40, 41]. Also, alternative models (beyond the naive
stacking of omic sources) could be proposed for the combination of the high-
dimensional omic sources of predictors which could be used as an alternative
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to our sequential approach. For example, we could consider group penaliza-
tion approaches, such as group lasso [42] or the recently proposed group ridge
[43]. However, it is unclear if they would adequately perform in our testing
context. All these topics are left as interesting lines of future research.
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Supplement A. Application to DILGOM data.
Supplementary analyses
Supplementary analysis 1
We check the impact of the sample size on the estimation of the predictive
ability of each of the considered sources of predictors for BMI in the DILGOM
data. The sample size is reduced (n = 50, n = 100, n = 200) in order to check
the robustness of the results based on the sequential double cross-validation
procedure.
Table S1: Application to DILGOM data. Sensitivity analysis: check impact
of sample size. P-values based on 1000 permutations
CV type Q2Metab Q
2
GE|Metab Q
2
G p-value
n = 246 α = 0,CVD,λopt 0.305 0.071 0.415 < 0.001
n = 100 α = 0,CVD,λopt 0.092 0.121 0.202 0.002
n = 50 α = 0,CVD,λopt 0.062 0.053 0.106 0.121
n = 248 α = 1,CVD,λopt 0.343 0.090 0.458 < 0.001
n = 100 α = 1,CVD,λopt 0.288 0.337 0.685 0.003
n = 50 α = 1,CVD,λopt 0.324 0.017 0.336 0.653
CV type Q2GE Q
2
Metab|GE Q
2
G p-value
n = 248 α = 0,CVD,λopt 0.092 0.194 0.327 < 0.001
n = 100 α = 0,CVD,λopt 0.116 0.095 0.191 < 0.001
n = 50 α = 0,CVD,λopt 0.037 0.051 0.099 0.073
n = 248 α = 1,CVD,λopt 0.277 0.102 0.453 < 0.001
n = 100 α = 1,CVD,λopt 0.149 0.123 0.269 0.031
n = 50 α = 1,CVD,λopt 0.175 0.546 0.774 < 0.001
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Supplementary analysis 2
Comparison of double cross-validation sequential approach to combination
models based on stacking different sources of predictors.
Table S2: DILGOM data. Q2 based on double cross-validation ridge and
lasso fits for single omic source (transcriptomics and metabolomics) models
and different alternatives to jointly consider both omic sources. Single source
refer to models based on transcriptomics (GE) and metabolomics (Metab)
only. ‘Stack’ refers to models based on the joint model based on stacking
the two sources. ‘Stack+std’ refers to stacking of previously scaled tran-
scriptomics and metabolomics. Sequential refers to the sequential procedure
presented in our manuscript. Metab|GE considers GE as primary source,
while GE|Metab considers metabolomics as primary source.
Single source Combination
GE Metab Stack Stack+std Sequential
Metab|GE GE|Metab
Ridge Q2 0.092 0.305 0.150 0.168 0.327 0.415
Lasso Q2 0.277 0.343 0.250 0.142 0.453 0.458
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Supplement B. Simulation study. Alternative
approaches
Simulation results based on two modification of the two-stage procedure pre-
sented in Section 2: CVS,λopt relies on single cross-validation (cross-validation
is used for model choice but predictions and therefore the residuals used as
outcome in the second stage are directly computed on the complete sample);
CVD,λ1se relies on over-penalization. Specifically, instead of taking λopt as
defined in the inner loop of the double cross-validation procedure presented
in Subsection 2.1., we choose a larger value for λ, namely λopt + 1s.e.(λopt).
Simulations for these two approaches are based on the same specifications
detailed in Subsection 3.1., considering p = 1000 and q = 100.
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Table S3: Ridge (α = 0). Mean estimates (and standard deviation in brack-
ets) of Q2X1 , Q
2
X2|X1 , Q
2
X1,X2
and rejection proportions of the permutation
test based on Q2X2|X1 along 500 Monte Carlo trials. p = 1000, q = 100.
Scenario CV type Q2X1 (Step 1) Q
2
X2|X1 (Step 2) Q
2
X1,X2
(Global) Rej. Prop.
n = 50, CVD,λ1se 0.70 (0.13) 0.02 (0.07) 0.73 (0.09) 0.048
1a n = 100, CVD,λ1se 0.76 (0.09) 0.00 (0.03) 0.77 (0.07) 0.030
n = 50, CVS ,λopt 0.95 (0.03) 0.06 (0.12) 0.97 (0.00) 0.014
n = 100, CVS ,λopt 0.92 (0.02) 0.02 (0.03) 0.98 (0.01) 0.016
n = 50, CVD,λ1se 0.09 (0.08) 0.00 (0.01) 0.10 (0.07) 0.042
1b n = 100, CVD,λ1se 0.16 (0.09) 0.00 (0.00) 0.16 (0.09) 0.074
n = 50, CVS ,λopt 0.87 (0.16) 0.04 (0.11) 0.98 (0.10) 0.048
n = 100, CVS ,λopt 0.69 (0.13) 0.01 (0.03) 0.94 (0.05) 0.018
n = 50, CVD,λ1se 0.79 (0.04) 0.00 (0.02) 0.79 (0.04) 0.034
1c n = 100, CVD,λ1se 0.84 (0.02) 0.00 (0.01) 0.84 (0.02) 0.056
n = 50, CVS ,λopt 0.97 (0.01) 0.04 (0.10) 0.99 (0.00) 0.014
n = 100, CVS ,λopt 0.95 (0.02) 0.02 (0.04) 0.99 (0.00) 0.012
n = 50, CVD,λ1se 0.79 (0.04) 0.00 (0.02) 0.79 (0.04) 0.056
1d n = 100, CVD,λ1se 0.86 (0.02) 0.00 (0.00) 0.86 (0.02) 0.044
n = 50, CVS ,λopt 0.97 (0.00) 0.04 (0.10) 0.99 (0.00) 0.028
n = 100, CVS ,λopt 0.97 (0.01) 0.01 (0.03) 0.99 (0.00) 0.020
n = 50, CVD,λ1se 0.04 (0.09) 0.01 (0.02) 0.05 (0.09) 0.088
2a n = 100, CVD,λ1se 0.02 (0.06) 0.01 (0.01) 0.01 (0.07) 0.073
n = 50,CVS , λopt 0.75 (0.21) 0.61 (0.16) 0.94 (0.18) 0.746
n = 100,CVS , λopt 0.74 (0.12) 0.66 (0.10) 0.96 (0.11) 0.972
n = 50, CVD,λ1se 0.61 (0.19) 0.08 (0.13) 0.71 (0.12) 0.170
2b n = 100, CVD,λ1se 0.64 (0.19) 0.01 (0.01) 0.78 (0.24) 0.258
n = 50, CVS ,λopt 0.94 (0.04) 0.20 (0.15) 0.99 (0.00) 0.116
n = 100, CVS ,λopt 0.91 (0.03) 0.14 (0.08) 0.99 (0.01) 0.498
n = 50, CVD,λ1se 0.05 (0.06) 0.01 (0.02) 0.06 (0.06) 0.100
2d n = 100, CVD,λ1se 0.08 (0.08) 0.01 (0.01) 0.08 (0.08) 0.217
n = 50, CVS ,λopt 0.68 (0.21) 0.14 (0.15) 0.96 (0.10) 0.032
n = 100, CVS ,λopt 0.61 (0.14) 0.12 (0.08) 0.93 (0.06) 0.202
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Table S4: Lasso (α = 1). Mean estimates (and standard deviation in brack-
ets) of Q2X1 , Q
2
X2|X1 , Q
2
X1,X2
and rejection proportions of the permutation
test based on Q2X2|X1 along 500 Monte Carlo trials. p = 1000, q = 100.
Scenario CV type Q2X1 (Step 1) Q
2
X2|X1 (Step 2) Q
2
X1,X2
(Global) Rej. Prop.
n = 50, CVD,λ1se 0.71 (0.07) 0.05 (0.06) 0.76 (0.06) 0.068
1a n = 100, CVD,λ1se 0.79 (0.04) 0.01 (0.01) 0.81 (0.04) 0.024
n = 50, CVS ,λopt 0.93 (0.04) 0.09 (0.14) 0.99 (0.01) 0.038
n = 100, CVS ,λopt 0.92 (0.03) 0.04 (0.05) 0.98 (0.01) 0.052
n = 50, CVD,λ1se 0.05 (0.05) 0.01 (0.03) 0.07 (0.06) 0.034
1b n = 100, CVD,λ1se 0.15 (0.07) 0.00 (0.02) 0.15 (0.07) 0.036
n = 50, CVS ,λopt 0.46 (0.33) 0.05 (0.12) 0.73 (0.32) 0.046
n = 100, CVS ,λopt 0.51 (0.17) 0.02 (0.06) 0.83 (0.11) 0.054
n = 50, CVD,λ1se 0.73 (0.06) 0.03 (0.06) 0.75 (0.07) 0.078
1c n = 100, CVD,λ1se 0.83 (0.03) 0.01 (0.02) 0.84 (0.03) 0.074
n = 50, CVS ,λopt 0.96 (0.02) 0.08 (0.15) 1.00 (0.00) 0.012
n = 100, CVS ,λopt 0.95 (0.02) 0.03 (0.05) 1.00 (0.01) 0.042
n = 50, CVD,λ1se 0.60 (0.07) 0.03 (0.05) 0.61 (0.07) 0.070
1d n = 100, CVD,λ1se 0.78 (0.04) 0.01 (0.02) 0.78 (0.04) 0.103
n = 50, CVS ,λopt 0.96 (0.00) 0.10 (0.15) 0.99 (0.00) 0.036
n = 100, CVS ,λopt 0.96 (0.01) 0.03 (0.06) 0.99 (0.01) 0.024
n = 50, CVD,λ1se 0.41(0.11) 0.17 (0.12) 0.45 (0.13) 0.782
2a n = 100, CVD,λ1se 0.50 (0.08) 0.28 (0.09) 0.86 (0.05) 1.000
n = 50, CVS ,λopt 0.71 (0.14) 0.50 (0.16) 0.98 (0.03) 0.614
n = 100, CVS ,λopt 0.71 (0.08) 0.59 (0.09) 0.97 (0.01) 0.958
n = 50, CVD,λ1se 0.67 (0.08) 0.08 (0.07) 0.76 (0.07) 0.130
2b n = 100, CVD,λ1se 0.75 (0.05) 0.05 (0.05) 0.92 (0.02) 0.424
n = 50, CVS ,λopt 0.91 (0.05) 0.20 (0.19) 0.99 (0.01) 0.072
n = 100, CVS ,λopt 0.90 (0.04) 0.13 (0.13) 0.98 (0.01) 0.380
n = 50, CVD,λ1se 0.03 (0.05) 0.02 (0.05) 0.05 (0.07) 0.098
2c n = 100, CVD,λ1se 0.10 (0.06) 0.01 (0.02) 0.10 (0.06) 0.283
n = 50, CVS ,λopt 0.36 (0.32) 0.10 (0.17) 0.68 (0.32) 0.106
n = 100, CVS ,λopt 0.42 (0.19) 0.09 (0.10) 0.54 (0.12) 0.257
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